Corvus Pharmaceuticals (CRVS) EPS (Diluted) Growth (3y) (2022 - 2026)
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) EPS (Diluted) Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -36.81% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 67.51% |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -19.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.34% |
| Mar 31, 2026 | -3.31% |
| Sep 30, 2025 | 23.30% |
| Jun 30, 2025 | 12.99% |
| Mar 31, 2025 | 49.13% |
| Sep 30, 2024 | -42.21% |
| Jun 30, 2024 | 38.65% |
| Mar 31, 2024 | 28.60% |
| Dec 31, 2023 | 31.07% |
| Sep 30, 2023 | 32.02% |
| Jun 30, 2023 | 32.77% |
| Mar 31, 2023 | 33.11% |
| Dec 31, 2022 | 32.67% |